Bace-1 Inhibitors Using Novel Edge-to-Face Interaction with Arg-296
Clarke, B., Cutler, L., Demont, E., Dingwall, C., Dunsdon, R., Hawkins, J., Howes, C., Hussain, I., Maile, G., Matico, R., Mosley, J., Naylor, A., O'Brien, A., Redshaw, S., Rowland, P., Soleil, V., Smith, K.J., Sweitzer, S., Theobald, P., Vesey, D., Walter, D.S., Wayne, G.(2010) Bioorg Med Chem Lett 20: 4639
- PubMed: 20579874 
- DOI: https://doi.org/10.1016/j.bmcl.2010.05.111
- Primary Citation of Related Structures:  
2XFI, 2XFJ, 2XFK - PubMed Abstract: 
Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. Herein, is described a series of potent inhibitors based on an hydroxyethylamine (HEA) transition state mimetic template. These inhibitors interact with the non prime side of the enzyme using a novel edge-to-face interaction with Arg-296.
Organizational Affiliation: 
Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R&D, New Frontiers Science Park, Harlow, Essex, UK.